Narcolepsy (HLA-DQB1*06:02P) Genotyping
Narcolepsy is a chronic sleep disorder characterized by: excessive daytime sleepiness, disrupted nocturnal sleep, rapid eye movement sleep (REM sleep) occurring at onset of sleep, and cataplexy. Other variable symptoms also associated with narcolepsy include: sleep paralysis and hypnagogic hallucinations. Narcolepsy results from the loss of hypocretin-1 and hypocretin-2, neurotransmitters produced by neurons located in the hypothalamus and brain stem.
Narcolepsy’s prevalence is approximately 25-50 per 100,000 people in the general population. Despite the multifactoral components present in narcolepsy, genetic factors play an integral role in disease manifestations, with the DQB1*0602 haplotype present in 95% of narcolepsy patients presenting with cataplexy. Genomic studies have also demonstrated a strong association of polymorphisms in the TCRα and TNFSF4 loci and narcolepsy, suggesting an autoimmune connection. Secondary narcolepsy is often associated with tumors, strokes, and vascular malformations in areas of the posterior hypothalamus or midbrain. Secondary narcolepsy is thought to be a result of direct brain injury, not the DQB1*0602 haplotype.
- Confirmative testing for patients with a clinical diagnosis of narcolepsy
- Supportive testing of patients presenting with an uncharacterized sleep disorder
- Supportive testing of individuals with inconclusive clinical histories and sleep studies
Positive for Narcolepsy: HLA-DQB1\*06:02 allele detected. Positive results does not establish a diagnosis of narcolepsy in the absence of other clinical support.
Negative for Narcolepsy: HLA-DQB1\*06:02 allele not detected. Negative results will decrease, but not eliminated diagnosis of narcolepsy. HLA-DQB1\*06:02 genotyping does not evaluate other genetic and non-genetic factors contributing to a narcolepsy diagnosis.
Negative for mutations analyzed (No mutation detected)
Whole blood EDTA, or ACD.
Samples stable at room temp or may be refrigerated. Frozen samples are unacceptable.
Stability
- Ambient: 5-7 days
- Refrigeration: 7-14 days
- Curr Opin Neurobiol. 2013 Oct;23(5):767-73. [PMID: 23725858]
- Int Rev Psychiatry. 2005 Dec;17(6):461-9. [PMID: 16401544]
- Adv Neuroimmunol. 1995;5(1):23-37. [PMID: 7795891]
- Br J Clin Pract. 1991 Summer;45(2):116-20. [PMID: 1793696]
- J Autoimmun. 2013 Jun;43:26-31. [PMID: 23497937]
- Sleep Med Rev. 2008 Apr;12(2):95-107, [PMID: 18291691]